Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

[1]  P. Libby,et al.  Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. , 2011, Journal of the American College of Cardiology.

[2]  V. Fuster,et al.  Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. , 2011, American heart journal.

[3]  R. Willette,et al.  Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia , 2011, Circulation.

[4]  R. Willette,et al.  Inhibition of p38 Mitogen-Activated Protein Kinase Reduces Inflammation After Coronary Vascular Injury in Humans , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[5]  R. Gropler,et al.  Adipose tissue imaging the potential and the challenge. , 2010, JACC. Cardiovascular imaging.

[6]  Y. Sheikine,et al.  FDG-PET imaging of atherosclerosis: Do we know what we see? , 2010, Atherosclerosis.

[7]  H. Sillesen,et al.  18FDG PET and ultrasound echolucency in carotid artery plaques. , 2010, JACC. Cardiovascular imaging.

[8]  H. Sillesen,et al.  Gene expression and 18FDG uptake in atherosclerotic carotid plaques , 2010, Nuclear medicine communications.

[9]  P. Libby,et al.  Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by PET imaging. , 2010, JACC. Cardiovascular imaging.

[10]  A. Langheinrich,et al.  Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression , 2010, Basic Research in Cardiology.

[11]  N. Aiyar,et al.  Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease , 2009, Journal of Pharmacology and Experimental Therapeutics.

[12]  B. Hutton,et al.  Vascular Inflammation Imaging with 18F-FDG PET/CT: When to Image? , 2009, Journal of Nuclear Medicine.

[13]  H. Hauner,et al.  Effects of tumour necrosis factor alpha (TNFα) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture , 1995, Diabetologia.

[14]  M. Pencina,et al.  C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study , 2008, Circulation. Cardiovascular quality and outcomes.

[15]  Anthony J. Muslin,et al.  MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. , 2008, Clinical science.

[16]  Eun Jeong Lee,et al.  Reversal of Vascular 18F-FDG Uptake with Plasma High-Density Lipoprotein Elevation by Atherogenic Risk Reduction , 2008, Journal of Nuclear Medicine.

[17]  Sameer Bansilal,et al.  Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations , 2008, Journal of Nuclear Medicine.

[18]  M. Robson,et al.  Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging , 2008, Atherosclerosis.

[19]  Udo Hoffmann,et al.  Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease Risk Factors, and Vascular Calcification in a Community-Based Sample: The Framingham Heart Study , 2008, Circulation.

[20]  R. Mirabile,et al.  p38 MAPK Inhibition Reduces Aortic Ultrasmall Superparamagnetic Iron Oxide Uptake in a Mouse Model of Atherosclerosis: MRI Assessment , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[21]  V. Fuster,et al.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. , 2007, Journal of the American College of Cardiology.

[22]  T. Imaizumi,et al.  Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. , 2007, Journal of the American College of Cardiology.

[23]  Masatoshi Ishibashi,et al.  Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. , 2006, Journal of the American College of Cardiology.

[24]  Ahmed Tawakol,et al.  In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. , 2006, Journal of the American College of Cardiology.

[25]  Takashi Kato,et al.  Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[27]  J. Egido,et al.  Intensive Treatment With Atorvastatin Reduces Inflammation in Mononuclear Cells and Human Atherosclerotic Lesions in One Month , 2005, Stroke.

[28]  E. Araki,et al.  Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase mediate macrophage proliferation induced by oxidized low-density lipoprotein. , 2004, Atherosclerosis.

[29]  S. R. Ferreira,et al.  Methods of estimation of visceral fat: advantages of ultrasonography. , 2003, Obesity research.

[30]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[31]  O. Prante,et al.  Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[33]  J. Pickard,et al.  Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography , 2002, Circulation.

[34]  R. Somwar,et al.  An Inhibitor of p38 Mitogen-activated Protein Kinase Prevents Insulin-stimulated Glucose Transport but Not Glucose Transporter Translocation in 3T3-L1 Adipocytes and L6 Myotubes* , 1999, The Journal of Biological Chemistry.

[35]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.